Fig. 5: Enhancing glioma microdialysate is enriched for plasma-derived metabolites.
From: Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
a Enrichment analysis was utilised to determine the enrichment of each patient’s enhancing vs. non-enhancing tumour catheters (ranked list: Cath. X vs. Y) for high-plasma versus low-plasma CSF (metabolite sets). Positive normalised enrichment scores (NES) indicate metabolic similarities to high-plasma CSF; negative NES indicate metabolic similarities to low-plasma CSF (* = FDR ≤ 0.05). b The rank of each metabolite from the significant enhancing versus non-enhancing glioma metabolite in Fig. 4b is shown for each patient (E: purple, rank 1, to NE: orange, rank 162), along with the metabolite’s rank in a bloody vs. clean CSF ranked fold-change list (bloody: red, 1 – clean: blue, 157). c Proposed model depicting the impact of blood-brain barrier disruption on the enhancing versus non-enhancing glioma extracellular metabolomes (created using BioRender).
